test

E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy (ECOG 7208)

Conditions

Colon

Trial Phase

Phase II

Trial Purpose and Description

Trial Purpose


Participation Guidelines

Age:
Gender:

Eligibility Criteria

Sponsor:
Eastern Cooperative Oncology Group
Dates:
01/15/2011
Last Updated:
Study HIC#:
1010007561